Meeting
2024 ASCO Genitourinary Cancers Symposium
Patient outcomes after therapy with 177Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC): A tertiary center experience.
Authors
Meryam Losee
Dana-Farber Cancer Institute, Boston, MA
Meryam Losee , Nuno Vaz , Jolivette Ritzer , Andrew Wolanski , Sudhir Bhimaniya , Atish Dipankar Choudhury , Hyewon Hyun , Emma Kelly , Kerry L. Kilbridge , Alicia K. Morgans , Mark Pomerantz , Matthew Robertson , Christopher Sakellis , Hina Shah , Rajitha Sunkara , Mary-Ellen Taplin , Xiao X. Wei , Bridget Whelpley , Praful Ravi , Heather Jacene
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 87)
DOI
10.1200/JCO.2024.42.4_suppl.87
Abstract #
87
Poster Bd #
D2
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Impact of race on outcomes to 177Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Avina Rami
Poster
2023 ASCO Annual Meeting
A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
First Author: Daniel J. George
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase 2 study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Teresa Alonso Gordoa
Poster
2021 Genitourinary Cancers Symposium
Outcomes in men with metastatic castrate-resistant prostate cancer treated with early platinum-based chemotherapy following an unsatisfactory response to androgen receptor (AR) inhibition as part of the phase II dynamic allocation modular sequential (DynAMo) trial.
First Author: Paul Vincent Viscuse